What is the price of target stock?
The price target of a stock is the price at which the stock is fairly valued with respect to its historical and projected earnings. When stocks are trading below and above their price targets, investors can maximize their rates of return by buying and selling. Stock price targets are often published by research analysts.
What is target stock price?
The stock has a market cap of $20.58 billion, a price-to-earnings ratio of 875.81, a PEG ratio of 2.71 and a beta of 1.25. ZoomInfo Technologies has a fifty-two week low of $37.86 and a fifty-two week high of $79.17.
What is target share price?
Three of SPXV's underlying holdings with notable upside to their analyst target prices are AMETEK Inc (Symbol: AME), Verisign Inc (Symbol: VRSN), and Trimble Inc (Symbol: TRMB). Although AME has traded at a recent price of $144.06/share, the average ...
What are stock price targets?
trading closer to a bullish pattern in the stock market. Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SBSW shares is $19.14 per share. Analysis on target price and performance of stocks is ...
How were Progenics Pharmaceuticals' earnings last quarter?
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) posted its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.19) EPS for...
Who are Progenics Pharmaceuticals' key executives?
Progenics Pharmaceuticals' management team includes the following people: Mr. Mark R. Baker , CEO & Director (Age 64) Mr. Patrick Fabbio , Exec...
Who are some of Progenics Pharmaceuticals' key competitors?
Some companies that are related to Progenics Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Re...
What other stocks do shareholders of Progenics Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Vonage (VG...
What is Progenics Pharmaceuticals' stock symbol?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."
What is Progenics Pharmaceuticals' stock price today?
One share of PGNX stock can currently be purchased for approximately $4.10.
How much money does Progenics Pharmaceuticals make?
Progenics Pharmaceuticals (NASDAQ:PGNX) has a market capitalization of $355.05 million and generates $34.99 million in revenue each year. The biote...
How many employees does Progenics Pharmaceuticals have?
Progenics Pharmaceuticals employs 79 workers across the globe.
What is Progenics Pharmaceuticals' official website?
The official website for Progenics Pharmaceuticals is www.progenics.com .
What is PGNX in prostate cancer?
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that the results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyLTM (18F-DCFPyL) in men with biochemical recurrence of prostate cancer will be presented in an oral session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. PyL is the Company’s PSMA-targeted small molecule positron emission tomography (PET) imaging agent designed to visualize prostate cancer.
Where is Progenics Pharmaceuticals located?
The company was founded in 1986 and is based in Tarrytown, New York.
Gilead Sciences Sues to Block Sellers of Counterfeit HIV Meds
Gilead Sciences uncovered a network that sold some $250 million of counterfeit versions of its HIV medications, a media report says.
Elon Musks Claps Back Over FSD, Starts Another Twitter Spat
"Green Hills Software is a pile of trash," the Tesla founder wrote on Twitter.
Fund Managers Stay Bullish on Stocks: Bank of America Survey
As of last week fund managers were 55% net overweight in stocks, compared with 77% net underweight in bonds, a Bank of America survey says.
Ethereum Most Volatile Crypto in New Year
Ethereum has been the most volatile cryptocurrency, based based on its standard deviation in the last 20 days.
Healthcare M&A Set For Lots of Deals in 2022
ShockWave among companies seen in play as Real Money's Kevin Curran runs down the factors driving mergers and acquisitions in the health industry.
Coinbase And Mastercard Want To Make It Easier For You To Buy NFTs
The companies have partnered on a credit-card enabled NFT marketplace.
Three Rules to Survive a Bear Market
Real Money's James 'Rev Shark' Deporre lists the keys to making it through big downturns.
